keyword
MENU ▼
Read by QxMD icon Read
search

meta antipsychotic

keyword
https://www.readbyqxmd.com/read/29772306/vascular-endothelial-growth-factor-in-patients-with-schizophrenia-a-systematic-review-and-meta-analysis
#1
REVIEW
Błażej Misiak, Filip Stramecki, Bartłomiej Stańczykiewicz, Dorota Frydecka, Alba Lubeiro
BACKGROUND: Accumulating evidence indicates that schizophrenia might be accompanied by abnormal vascularization. Vascular endothelial growth factor (VEGF) is one of key molecules involved in the development of vessels with vasodilatory activities. OBJECTIVES: We aimed to perform a systematic review and meta-analysis of studies investigating serum or plasma levels of VEGF in patients with schizophrenia and first-episode psychosis (FEP). METHODS: Electronic databases were searched from their inception until 18th Apr 2018...
May 14, 2018: Progress in Neuro-psychopharmacology & Biological Psychiatry
https://www.readbyqxmd.com/read/29762677/anti-dementia-drugs-for-psychopathology-and-cognitive-impairment-in-schizophrenia-a-systematic-review-and-meta-analysis
#2
Taro Kishi, Toshikazu Ikuta, Kazuto Oya, Shinji Matsunaga, Yuki Matsuda, Nakao Iwata
Background: We conducted a systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials of anti-dementia drugs plus antipsychotics (ADD+AP) for schizophrenia. Methods: Primary outcomes of efficacy and safety included improving overall symptoms (Positive and Negative Syndrome Scale and Brief Psychiatric Rating Scale scores) and all-cause discontinuation, respectively. Other outcomes included psychopathology subscales (positive, negative, general, and anxiety/depressive symptoms), cognitive function (attention/vigilance, reasoning/problem solving, social cognition, speed of processing, verbal learning, visual learning, working memory, and cognitive control/executive function), Mini-Mental State Examination (MMSE) scores, treatment discontinuation due to adverse events and inefficacy, and individual adverse events...
May 14, 2018: International Journal of Neuropsychopharmacology
https://www.readbyqxmd.com/read/29758999/movement-disorders-associated-with-antipsychotic-medication-in-people-with-schizophrenia-an-overview-of-cochrane-reviews-and-meta-analysis
#3
Davide Martino, Vikram Karnik, Sydney Osland, Thomas R E Barnes, Tamara M Pringsheim
Movement disorders associated with antipsychotic medications are relatively common, stigmatising, and potentially disabling. Their prevalence in people with psychosis who are prescribed second-generation antipsychotics (SGAs) is uncertain, as is their level of recognition by clinicinas. We conducted meta-analyses of randomised controlled trials included in the Cochrane Database of Systematic Reviews on schizophrenia and schizophrenia-like psychoses to estimate the prevalence of new-onset dystonia, akathisia, parkinsonism, and tremor with SGAs (amisulpride, asenapine, aripiprazole, clozapine, olanzapine, paliperidone, quetiapine, risperidone, L-sulpiride, and ziprasidone) approved in Canada and the UK, comparing them with haloperidol and chlorpromazine...
January 1, 2018: Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie
https://www.readbyqxmd.com/read/29743584/is-psychosis-a-multisystem-disorder-a-meta-review-of-central-nervous-system-immune-cardiometabolic-and-endocrine-alterations-in-first-episode-psychosis-and-perspective-on-potential-models
#4
REVIEW
Toby Pillinger, Enrico D'Ambrosio, Robert McCutcheon, Oliver D Howes
People with psychotic disorders show abnormalities in several organ systems in addition to the central nervous system (CNS); and this contributes to excess mortality. However, it is unclear how strong the evidence is for alterations in non-CNS systems at the onset of psychosis, how the alterations in non-CNS systems compare to those in the CNS, or how they relate to symptoms. Here, we consider these questions, and suggest potential models to account for findings. We conducted a systematic meta-review to summarize effect sizes for both CNS (focusing on brain structural, neurophysiological, and neurochemical parameters) and non-CNS dysfunction (focusing on immune, cardiometabolic, and hypothalamic-pituitary-adrenal (HPA) systems) in first-episode psychosis (FEP)...
May 9, 2018: Molecular Psychiatry
https://www.readbyqxmd.com/read/29732913/augmentation-strategies-for-clozapine-refractory-schizophrenia-a-systematic-review-and-meta-analysis
#5
Dan J Siskind, Michael Lee, Arul Ravindran, Qichen Zhang, Evelyn Ma, Balaji Motamarri, Steve Kisely
BACKGROUND: Although clozapine is the most effective medication for treatment refractory schizophrenia, only 40% of people will meet response criteria. We therefore undertook a systematic review and meta-analysis of global literature on clozapine augmentation strategies. METHODS: We systematically reviewed PubMed, PsycInfo, Embase, Cochrane Database, Chinese Biomedical Literature Service System and China Knowledge Resource Integrated Database for randomised control trials of augmentation strategies for clozapine resistant schizophrenia...
May 1, 2018: Australian and New Zealand Journal of Psychiatry
https://www.readbyqxmd.com/read/29730395/profiling-inflammatory-signatures-of-schizophrenia-a-cross-sectional-and-meta-analysis-study
#6
Dorota Frydecka, Małgorzata Krzystek-Korpacka, Alba Lubeiro, Filip Stramecki, Bartłomiej Stańczykiewicz, Jan Aleksander Beszłej, Patryk Piotrowski, Kamila Kotowicz, Monika Szewczuk-Bogusławska, Edyta Pawlak-Adamska, Błażej Misiak
We aimed to profile a broad panel of inflammatory markers in patients with schizophrenia and healthy controls. Additionally, we performed a meta-analysis of chemokine alterations that have not been subjected to quantitative synthesis so far. We recruited 78 patients with schizophrenia and 78 healthy controls, and measured inflammatory markers using the Luminex technology. After adjustment for multiple testing, we found elevated levels of interleukin (IL)-1 receptor antagonist (IL-1RA), IL-6, IL-7, IL-8, IL-9, IL-10, IL-13, interferon-γ, eotaxin-1, granulocyte-macrophage colony-stimulating factor (GM-CSF), monocyte chemoattractant protein-1 (MCP-1), platelet-derived growth factor with two B subunits (PDGF-BB), macrophage inflammatory protein (MIP)-1α, MIP-1β, vascular endothelial growth factor A (VEGF-A) and RANTES in multiple-episode schizophrenia (MES) patients...
May 3, 2018: Brain, Behavior, and Immunity
https://www.readbyqxmd.com/read/29730043/identifying-the-genetic-risk-factors-for-treatment-response-to-lurasidone-by-genome-wide-association-study-a-meta-analysis-of-samples-from-three-independent-clinical-trials
#7
Jiang Li, Antony Loebel, Herbert Y Meltzer
A genome-wide association study (GWAS) of response of schizophrenia patients to the atypical antipsychotic drug, lurasidone, based on two double-blind registration trials, identified SNPs from four classes of genes as predictors of efficacy, but none were genome wide significant (GWS). After inclusion of data from a third lurasidone trial, meta-analysis identified a GWS marker and other findings consistent with our first study. The primary end-point was change in Total Positive and Negative Syndrome Scale (PANSS) between baseline and last observation carried forward...
May 2, 2018: Schizophrenia Research
https://www.readbyqxmd.com/read/29727467/pharmacological-interventions-for-apathy-in-alzheimer-s-disease
#8
REVIEW
Myuri T Ruthirakuhan, Nathan Herrmann, Eleenor H Abraham, Sarah Chan, Krista L Lanctôt
BACKGROUND: Despite the high prevalence of apathy in Alzheimer's disease (AD), and its harmful effects, there are currently no therapies proven to treat this symptom. Recently, a number of pharmacological therapies have been investigated as potential treatments for apathy in AD. OBJECTIVES: Objective 1: To assess the safety and efficacy of pharmacotherapies for the treatment of apathy in Alzheimer's disease (AD).Objective 2: To assess the effect on apathy of pharmacotherapies investigated for other primary outcomes in the treatment of AD...
May 4, 2018: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29697804/clozapine-and-long-term-mortality-risk-in-patients-with-schizophrenia-a-systematic-review-and-meta-analysis-of-studies-lasting-1-1-12-5-years
#9
Jentien M Vermeulen, Geeske van Rooijen, Marita P J van de Kerkhof, Arjen L Sutterland, Christoph U Correll, Lieuwe de Haan
Introduction: Patients with schizophrenia have an elevated mortality risk compared to the general population, with cardiovascular-related deaths being the leading cause. The role of clozapine use in the long-term mortality risk is unclear. While clozapine treatment may increase the risk for cardiovascular mortality, it may have protective effects regarding suicidal behavior. Methods: We systematically searched EMBASE, MEDLINE, and PsycINFO and reviewed studies that used a long-term follow-up (ie, >52 weeks) and reported on mortality in adults diagnosed with schizophrenia-spectrum disorders who had received clozapine treatment...
April 25, 2018: Schizophrenia Bulletin
https://www.readbyqxmd.com/read/29688914/antipsychotic-drug-exposure-and-risk-of-fracture-a-systematic-review-and-meta-analysis-of-observational-studies
#10
Davide Papola, Giovanni Ostuzzi, Lehana Thabane, Gordon Guyatt, Corrado Barbui
To investigate the extent to which exposure to first-generation and second-generation antipsychotics (APs) is associated with an increased risk of fractures, with a particular focus on hip fractures, and to ascertain the risk associated with exposure to individual drugs. We included observational studies that reported data on fractures in individuals exposed to APs compared with unexposed individuals or individuals with previous exposure. We extracted information on study design, source of data, population characteristics, outcomes of interest, matching and confounding factors, and used a modified version of the Newcastle-Ottawa Scale to judge study risk of bias...
April 23, 2018: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/29682546/melatonin-for-atypical-antipsychotic-induced-metabolic-adverse-effects-a-meta-analysis-of-randomized-controlled-trials
#11
Ashwin Kamath, Zahoor Ahmad Rather
The objective of our study was to determine the effect of melatonin administration on atypical antipsychotic-induced metabolic adverse effects in patients with psychiatric disorders. A systematic search was performed in PUBMED, Cochrane Library, Scopus, Web of Science, and EBSCOhost electronic databases. Randomized controlled trials studying the effect of melatonin on antipsychotic-induced metabolic adverse effects were identified and subjected to meta-analysis. Four studies were included in the meta-analysis, including 57 patients on melatonin and 61 patients on placebo...
2018: BioMed Research International
https://www.readbyqxmd.com/read/29679069/pharmacological-treatment-of-adult-bipolar-disorder
#12
REVIEW
Ross J Baldessarini, Leonardo Tondo, Gustavo H Vázquez
We summarize evidence supporting contemporary pharmacological treatment of phases of BD, including: mania, depression, and long-term recurrences, emphasizing findings from randomized, controlled trials (RCTs). Effective treatment of acute or dysphoric mania is provided by modern antipsychotics, some anticonvulsants (divalproex and carbamazepine), and lithium salts. Treatment of BD-depression remains unsatisfactory but includes some modern antipsychotics (particularly lurasidone, olanzapine + fluoxetine, and quetiapine) and the anticonvulsant lamotrigine; value and safety of antidepressants remain controversial...
April 20, 2018: Molecular Psychiatry
https://www.readbyqxmd.com/read/29677175/are-antipsychotics-effective-for-the-prevention-of-postoperative-delirium
#13
Viviana Castro, Rami Guinguis, Marcela Carrasco
INTRODUCTION: Antipsychotics have been proposed as a pharmacological alternative to prevent postoperative delirium. Nonetheless, their actual clinical benefits and harms are a matter of debate. METHODS: To answer this question, we used Epistemonikos, the largest database of systematic reviews in health, which is maintained by screening multiple information sources, including MEDLINE, EMBASE, Cochrane, among others. We extracted data from the chosen systematic reviews, reanalyzed the data from the primary studies, conducted a meta-analysis and generated a summary of findings table using the GRADE approach...
April 20, 2018: Medwave
https://www.readbyqxmd.com/read/29672801/antisuicidal-effects-in-mood-disorders-are-they-unique-to-lithium
#14
Leonardo Tondo, Ross J Baldessarini
INTRODUCTION: Suicidal behavior is strongly associated with depression in major depressive (MDD) and bipolar (BD) disorders, especially with associated behavioral activation, dysphoria, or agitation. A rare intervention with evidence of suicide risk-reducing as well as mood-stabilizing effects in mood disorder patients is lithium. METHODS: We reviewed available research evidence on associations of long-term treatment with lithium with risk of suicidal behavior. We meta-analyzed 12 randomized trials in 10 reports (with at least 1 suicide in either treatment arm) including both BD and MDD subjects, with particular attention to comparisons of lithium with placebo or other pharmacological treatments...
April 19, 2018: Pharmacopsychiatry
https://www.readbyqxmd.com/read/29670200/effectiveness-of-traditional-chinese-medicineas-as-an-adjunct-therapy-for-refractory-schizophrenia-a-systematic-review-and-meta-analysis
#15
Yan-Yan Wei, Wan-Fu Lin, Tian-Hong Zhang, Yun-Xiang Tang, Ji-Jun Wang, Mao-Feng Zhong
Although recent studies focused on traditional Chinese medicine (TCM) for the treatment of refractory schizophrenia have reported that it may be beneficial, there is still lack of convincing evidence and critical meta-analytic work regarding its effectiveness as an adjunctive therapy. Therefore, we performed a meta-analysis to investigate the effectiveness of TCM in combination with antipsychotics for refractory schizophrenia. Fourteen articles involving 1725 patients published as of December 2016 were included which compared antipsychotic therapies to either TCM alone, or TCM as an adjunctive therapy...
April 18, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29602172/no-differences-in-olanzapine-and-risperidone-related-weight-gain-between-women-and-men-a-meta-analysis-of-short-and-middle-term-treatment
#16
G Schoretsanitis, M Drukker, J Van Os, K R J Schruers, M Bak
OBJECTIVE: A plethora of data deriving from single studies as well as meta-analyses demonstrates that weight gain is associated with the exposure to the majority of antipsychotics (AP). However, potential sex differences have widely evaded the attention of AP treatment trials. It is hypothesised that female patients gain more weight compared with male patients due to their enhanced susceptibility to adverse drug reactions. METHOD: A meta-analysis was conducted using clinical trials of AP that reported weight change separately for female and male patients...
March 30, 2018: Acta Psychiatrica Scandinavica
https://www.readbyqxmd.com/read/29599930/does-antipsychotic-drug-use-increase-the-risk-of-long-term-mortality-a-systematic-review-and-meta-analysis-of-observational-studies
#17
Chunsong Yang, Zilong Hao, Jinhui Tian, Wei Zhang, Wenting Li, Ling-Li Zhang, Fujian Song
Antipsychotics (AP) are widely used to treat schizophrenia and other psychiatric disorders. However, the association between the AP use and mortality risk is controversial. We searched PubMed, EMBASE, MEDLINE, PsycINFO, CINAHL, the Cochrane Library and four Chinese databases from inception to June 2016. All observational cohort or case-control studies reporting data on mortality outcomes in individuals exposed to AP drugs were included. This systematic review included 68 studies involving 4,812,370 participants...
March 13, 2018: Oncotarget
https://www.readbyqxmd.com/read/29587340/genetic-variations-associated-with-sleep-disorders-in-patients-with-schizophrenia-a-systematic-review
#18
REVIEW
Konstantinos Assimakopoulos, Katerina Karaivazoglou, Maria Skokou, Marina Kalogeropoulou, Panagiotis Kolios, Philippos Gourzis, George P Patrinos, Evangelia Eirini Tsermpini
Background: Schizophrenic patients commonly suffer from sleep disorders which are associated with acute disease severity, worsening prognoses and a poorer quality of life. Research is attempting to disentangle the complex interplay between schizophrenia and sleep disturbances by focusing not only on demographic and clinical characteristics, but also on the identification of genetic factors. Methods: Here, we performed a systematic literature review on the topic of genetic variations in sleep-disordered schizophrenic patients in an attempt to identify high quality investigations reporting scientifically sound and clinically useful data...
March 24, 2018: Medicines (Basel, Switzerland)
https://www.readbyqxmd.com/read/29580804/neurometabolite-levels-in-antipsychotic-na%C3%A3-ve-free-patients-with-schizophrenia-a-systematic-review-and-meta-analysis-of-1-h-mrs-studies
#19
REVIEW
Yusuke Iwata, Shinichiro Nakajima, Eric Plitman, Yukiko Mihashi, Fernando Caravaggio, Jun Ku Chung, Julia Kim, Philip Gerretsen, Masaru Mimura, Gary Remington, Ariel Graff-Guerrero
BACKGROUND: Studies using proton magnetic resonance spectroscopy (1 H-MRS) have reported altered neurometabolite levels in patients with schizophrenia. However, results are possibly confounded by the influence of antipsychotic (AP). Thus, this meta-analysis aimed to examine neurometabolite levels in AP-naïve/free patients with schizophrenia. METHODS: A literature search was conducted using Embase, Medline, and PsycINFO to identify studies that compared neurometabolite levels in AP-naïve/free patients with schizophrenia to healthy controls (HCs)...
March 23, 2018: Progress in Neuro-psychopharmacology & Biological Psychiatry
https://www.readbyqxmd.com/read/29570965/can-aripiprazole-worsen-psychosis-in-schizophrenia-a-meta-analysis-of-double-blind-randomized-controlled-trials
#20
Hiroyoshi Takeuchi, Ali Fathi, Sadhana Thiyanavadivel, Ofer Agid, Gary Remington
BACKGROUND: Numerous case reports have reported psychotic worsening when switching to or adding aripiprazole in patients with schizophrenia. The risk of psychotic worsening related to aripiprazole was evaluated through a systematic review and meta-analysis. DATA SOURCES: MEDLINE, Embase, and Cochrane Central Register of Controlled Trials were systematically searched using the following keywords: (schizophr* or schizoaff*) AND aripiprazole, with a limitation of randomized controlled trial and English language (last search: September 9, 2016) by the authors in an independent fashion...
March 2018: Journal of Clinical Psychiatry
keyword
keyword
109203
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"